Oculis (OCS) investor relations material

Opening remarks and agenda

• Meeting convened in compliance with statutory notice and agenda published in the Swiss Official Gazette of Commerce on April 21, 2026.

• All formalities fulfilled, meeting declared open with no objections raised.

• Secretary, vote counter, auditors, independent proxy, and notary introduced; voting procedures explained.

Financial performance review

• Cash and short-term investments reached CHF 213.0 million ($268.7 million) at end of 2025, up from CHF 98.7 million ($109.0 million) in 2024, mainly due to $210.0 million equity financings.

• Strong balance sheet with no debt and cash runway into 2H 2029, excluding a CHF 100 million loan facility.

• R&D expenses accounted for 69% of total operating expenses, rising to CHF 57.1 million ($68.7 million), mainly due to DIAMOND phase III trials.

• FY2025 net loss was CHF 99.0 million ($119.1 million), up from CHF 85.8 million ($97.4 million) in FY2024, reflecting increased R&D and personnel costs.

Board and executive committee updates

• Board members and director nominee present; all board and executive committee members proposed for re-election or election.

• Senior management and leadership team expanded with experienced professionals to support clinical stage asset delivery.